Key takeaways for New York
- • No GLP-1 is FDA-labeled for prediabetes — use is off-label.
- • Eligibility may still apply if BMI 30+ or 27+ with comorbidity (Wegovy/Zepbound).
- • Roughly 80-95% of prediabetic adults revert to normoglycemia in major trials.
- • New York Medicaid coverage rules apply for Prediabetes patients in New York — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Prediabetes
No GLP-1 drug carries an FDA prediabetes indication. However, in obese prediabetic adults, Wegovy and Zepbound are approved on the basis of BMI/comorbidity criteria, and both have been shown in trial post-hoc analyses to convert prediabetes back to normoglycemia in the majority of treated patients. Evidence grade: B (extrapolation from RCT subgroups). Lifestyle therapy and metformin remain first-line per ADA. GLP-1 use specifically for prediabetes is off-label and should be discussed with a physician.
New York-specific context
New York has telehealth access concentrated in New York City, Buffalo, Yonkers metros, with additional reach to Rochester and Syracuse. NewYork-Presbyterian, NYU Langone, Mount Sinai, Northwell Health is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at www.health.ny.gov.
New Yorktelehealth & pricing rules
- • New York requires a live video consultation before a GLP-1 prescription.
- • New York allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in New York: ~$312/mo (compounded options often lower, brand higher).
State telehealth statutes change — verify current rules with your provider before booking.